The Media Corner offers journalists the latest news from the last EBMT Annual Meeting, press releases, and press clippings. If you are interested in the EBMT Newsletters, you may access them via the link below the press clippings.
The EBMT and the EHA announce a strategic partnership to empower Europe to become a global leader in the cellular therapy field for haematological diseases.
The Gemeinsame Bundesausschuss (G-BA) published its directions on the treatment of German patients with CAR T-cell therapies.
The EBMT announced the results of the phase III RACE trial during EBMTs virtual 46th Annual Meeting.
The EBMT announces a new collaboration with Kite, a Gilead Company, to study the long-term outcomes of patients treated with Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor T cell (CAR T) therapy.
Copyright disclaimer: Please credit EBMT as the source of the image. Examples: Photo: EBMT; Image: EBMT. The image must not be used to state or imply the endorsement by EBMT or any EBMT employee of a process or service, or used in any other manner that might mislead. If the image is to be used in advertising or any commercial promotion, layout and copy must be submitted to EBMT beforehand for approval.
Click on the photos below to access the photo galleries from the most recent Annual Meetings.